Lineage Cell Therapeutics (LCTX) Tax Provisions (2014 - 2023)

Lineage Cell Therapeutics' Tax Provisions history runs 5 years deep, the most recent figure standing at -$1.8 million for Q1 2023.

• In Q1 2023, Tax Provisions changed N/A year-over-year to -$1.8 million; the TTM figure through Dec 2023 stood at -$1.8 million (up 87.62% YoY), while the FY2025 annual figure was -$5.3 million, changed N/A from the prior year.
• Tax Provisions for Q1 2023 stood at -$1.8 million, down from -$41000.0 in the prior quarter.
• The five-year high for Tax Provisions was $4.4 million in Q1 2019, with the low at -$14.0 million in Q4 2019.
• The 4-year median for Tax Provisions is $229500.0 (2022), against an average of -$1.2 million.
• Peak annual rise in Tax Provisions reached 149.41% in 2022, while the deepest fall reached 149.41% in 2022.
• Lineage Cell Therapeutics' Tax Provisions stood at -$14.0 million in 2019, then soared by 92.78% to -$1.0 million in 2021, then jumped by 95.95% to -$41000.0 in 2022, then sank by 4297.56% to -$1.8 million in 2023.
• Business Quant data shows LCTX's Tax Provisions at -$1.8 million in Q1 2023, -$41000.0 in Q4 2022, and $500000.0 in Q3 2022.